Document Type: Short Communication

Authors

1 Dept. of Anatomical Pathology, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia

2 Dept. of Radiology, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia

3 Dept. of Ear Nose Throat Head and Neck Surgery, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Abstract

Background: Overexpression of Rad51 protein in many tumor cells has been proven to increase radioresistance and can be related to the resistance of chemosensitivity of tumor cells. This preliminary study was conducted to determine the relationship between the Rad51 expression level in nasopharyngeal carcinoma and the response of the treatment based on the measurement of the tumor reduction. Methods:Thirteen cases of the NPCs were analyzed. The expression levels of the Rad51 were examined from the pretreatment biopsies. Furthermore, tumor reductions were determined based on the change in sum longest diameter of the nasopharyngeal CT-scan before and after therapy. Results: The expression level of the Rad51 was associated with the reduction of tumor mass.       The P value was 0.049 and the correlation coefficient was 0.479. Conclusion:The tumor cells Rad51 expression levels may affect the tumor reduction of NPC after the therapy.

Keywords

Main Subjects

  1. Boyle P, Levin B, editors. World Health Organization: World Cancer Report 2008. Lyon: IARC Press; 2008.
  2. El-Sherbieny E, Rashwan H, Lubis SH, Choi VJ. Prognostic factors in patients with nasopharyngeal carcinoma treated in hospital Kuala Lumpur.Asian Pac J Cancer Prev 2011;12(7):1739-43.
  3. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012 Apr;31(4):185-96.
  4. Chan JKC, Bray F, McCarron P et al. Nasopharyngeal carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p.82-96.
  5. Jia WH, Qin HD. Non-viral environmental risk factors for nasopharyngeal carcinoma: a systematic review. Semin Cancer Biol 2012 Apr;22(2):117-26.
  6. Gruhne B, Sompallae R, Masucci MG. Three Epstein–Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 2009 Nov 12;28(45):3997-4008.
  7. Qin HD, Shugart YY, Bei JX, Pan QH, Lina C, Feng QS, et al. Comprehensive pathway-based association study of DNA repair gene variants and the risk of nasopharyngeal carcinoma. Cancer Res 2011 Apr 15;71(8): 3000–8.
  8. Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011 Rosetta Stone for NPC: genetic, viral infection, and other environmental factors. Semin Cancer Biol 2012 Apr; 22(2):107-16.
  9. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008 May 3;7(5):686-93.
  10. Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res 2012 Jul;40(13):5795-818.
  11. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008 Jan;18(1):99-113.
  12. Henning W, Stürzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumor progression and therapy resistance. Toxicology 2003 Nov 15;193(1-2):91-109.
  13. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998 Jun 15;26(12): 2859–64.
  14. Taghizadeh M, Khoei S, Nikoofar AR, Ghamsari L, Goliaei B. The role of Rad51 protein in radioresistance of spheroid model of DU145 prostate carcinoma cell line. Iran J Radiat Res 2009;7(1):19-25.
  15. Hannay JAF, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PWT, et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007 May;6(5):1650-60.
  16. Takenaka T, Yoshino I, Hidenori K, Ohba T, Yohena T, Osoegawa A, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007 Aug 15;121(4):895-900.
  17. Connell PP, Jayathilaka K, Haraf D, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 2006 May;28(5):1113-9.
  18. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005 Jul 11;93(1):137-43.
  19. Chan ATC, Gregoire V, Lefebvre JL, Licitra L, Felip E. Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii83–vii85.
  20. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986 Oct 46(10):5419-25.
  21. Padhani AR, Olllivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 2001 Nov;74(887):983-6.
  22. Jayakumar S, Bhilwade HN, Pandeh BN, Sandur SK, Chaubey RC. The potential value of the neutral comet assay and the expression of genes associated with    DNA damage in assessing the radiosensitivity of tumor cells. Mutat Res 2012 Oct 9;748(1-2):52-9.